EVLO Evelo Biosciences Inc.

Evelo Biosciences Inc.

Biotechnology: Pharmaceutical Preparations

Health Care

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

IPO Year: 2018

Exchange: NASDAQ

Website: evelobio.com

Peers

$KLDO

$CDAK

$FHTX

Recent Analyst Ratings for Evelo Biosciences Inc.

Date	Price Target	Rating	Analyst
11/2/2021	$44.00 → $41.50	Market Outperform	JMP Securities
11/1/2021	$12.00	Neutral → Buy	Chardan Capital Markets
6/23/2021	$36.00 → $38.00	Market Outperform	JMP Securities
6/23/2021	$28.00	Overweight	Cantor Fitzgerald

See more ratings

Evelo Biosciences Inc.

Peers

Recent Analyst Ratings for Evelo Biosciences Inc.

Evelo Biosciences Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Bodmer Mark converted options into 6,625 shares and sold $1,044 worth of shares (3,163 units at $0.33), increasing direct ownership by 16% to 25,732 units (SEC Form 4)

Mchale Duncan converted options into 6,500 shares and sold $1,024 worth of shares (3,103 units at $0.33), increasing direct ownership by 25% to 16,984 units (SEC Form 4)

Gill Simba sold $57 worth of shares (172 units at $0.33) and converted options into 1,172 shares, increasing direct ownership by 6% to 17,758 units (SEC Form 4)

Thorell Marella converted options into 6,500 shares and sold $598 worth of shares (1,811 units at $0.33), increasing direct ownership by 27% to 22,259 units (SEC Form 4)

Bodmer Mark sold $2,262 worth of shares (6,854 units at $0.33) and converted options into 12,500 shares, increasing direct ownership by 34% to 22,270 units (SEC Form 4)

Mchale Duncan converted options into 12,500 shares and sold $2,262 worth of shares (6,854 units at $0.33), increasing direct ownership by 71% to 13,587 units (SEC Form 4)

Thorell Marella converted options into 12,500 shares and sold $1,320 worth of shares (3,999 units at $0.33), increasing direct ownership by 94% to 17,570 units (SEC Form 4)

Gill Simba sold $7,864 worth of shares (1,996 units at $3.94) and converted options into 15,000 shares, increasing direct ownership by 346% to 16,758 units (SEC Form 4)

SEC Form 4 filed by Bodmer Mark

SEC Form 4 filed by Thorell Marella

Evelo Biosciences Inc. SEC Filings

SEC Form EFFECT filed by Evelo Biosciences Inc.

SEC Form 15-12G filed by Evelo Biosciences Inc.

SEC Form S-8 POS filed by Evelo Biosciences Inc.

SEC Form S-8 POS filed by Evelo Biosciences Inc.

Evelo Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form POS AM filed by Evelo Biosciences Inc.

SEC Form 25-NSE filed by Evelo Biosciences Inc.

SEC Form DEFA14A filed by Evelo Biosciences Inc.

SEC Form DEF 14A filed by Evelo Biosciences Inc.

Evelo Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing